Philippe Bedard
Philippe Bedard
Princess Margaret Cancer Centre
Email verificata su uhn.ca
Titolo
Citata da
Citata da
Anno
Tumour heterogeneity in the clinic
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355-364, 2013
9262013
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium
Cancer discovery 7 (8), 818-831, 2017
3792017
The genetic basis for cancer treatment decisions
JE Dancey, PL Bedard, N Onetto, TJ Hudson
Cell 148 (3), 409-420, 2012
3182012
Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
HA Azim, S Michiels, PL Bedard, SK Singhal, C Criscitiello, M Ignatiadis, ...
Clinical cancer research 18 (5), 1341-1351, 2012
2952012
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis
FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ...
Journal of the National Cancer Institute 106 (1), djt319, 2014
2842014
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ...
Nature 563 (7732), 579-583, 2018
2682018
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy
F Cardoso, PL Bedard, EP Winer, O Pagani, E Senkus-Konefka, ...
Journal of the National Cancer Institute 101 (17), 1174-1181, 2009
2602009
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ...
New England Journal of Medicine 382 (7), 597-609, 2020
2592020
Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance
C Kollmannsberger, T Tandstad, PL Bedard, G Cohn-Cedermark, ...
J Clin Oncol 33 (1), 51-7, 2015
2312015
Luminal-B breast cancer and novel therapeutic targets
B Tran, PL Bedard
Breast Cancer Research 13 (6), 1-10, 2011
2242011
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with …
PL Bedard, J Tabernero, F Janku, ZA Wainberg, L Paz-Ares, ...
Clinical Cancer Research 21 (4), 730-738, 2015
2142015
Cancer genomics: technology, discovery, and translation
B Tran, JE Dancey, S Kamel-Reid, JD McPherson, PL Bedard, AM Brown, ...
J Clin Oncol 30 (6), 647-660, 2012
1852012
AKT inhibition in solid tumors with AKT1 mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251, 2017
1692017
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ...
Genome medicine 8 (1), 1-12, 2016
1492016
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
TW Chen, AR Razak, PL Bedard, LL Siu, AR Hansen
Annals of Oncology 26 (9), 1824-1829, 2015
1432015
Novel patterns of response under immunotherapy
E Borcoman, Y Kanjanapan, S Champiat, S Kato, V Servois, R Kurzrock, ...
Annals of Oncology 30 (3), 385-396, 2019
1392019
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, ...
Annals of Oncology 29 (9), 1895-1902, 2018
1272018
Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer
HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ...
Clinical Cancer Research 24 (12), 2804-2811, 2018
1222018
Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
E de Azambuja, PL Bedard, T Suter, M Piccart-Gebhart
Targeted oncology 4 (2), 77-88, 2009
1222009
Abstract S5-07: preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast …
HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ...
Cancer research 76 (4 Supplement), S5-07-S5-07, 2016
1192016
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20